Biolines Weekender is BioNJ’s e-newsletter featuring the latest happenings in R&D, as well as the incredible innovation coming from New Jersey’s robust life sciences ecosystem. Click here to subscribe to our mailing list.
Welcome to the first edition of the BioLines Weekender for 2022!
Happy New Year!
With the onset of 2022 comes new hope and encouragement for fresh opportunities and possibilities. Our industry remains focused and dedicated to what it does best…bringing new medical innovation to Patients throughout the world! Although 2021 proved to be challenging as we continued our fight against COVID-19, New Jersey’s robust life sciences ecosystem didn’t miss a beat with 34 new FDA drug approvals – representing nearly 40% of all new approvals! More…
Things on the policy front have been heating up with the New Jersey Legislature’s post-election “lame duck” session continuing through mid-January.
In particular, BioNJ continues to urge lawmakers in New Jersey to oppose A-2418/S-1066 which would threaten Patients, health equity and the very innovations that so many Patients rely on. Prescription Drug Affordability Boards provide little in terms of savings to consumers and impede the investment needed by small and emerging biopharmaceutical companies working to discover tomorrow’s cures. Recently, BioNJ released a white paper, “Prescription Drug Affordability Boards: Myths vs. Facts on Drug Supply Chain,” that corrects the record on several common myths about Prescription Drug Affordability Boards (PDAB) and explains their harmful impact. More…
Earlier this week, BioNJ announced its roster of notable speakers for BioNJ’s Seventh Annual Inspiring Women in STEM Conference, taking place virtually on Friday, December 3. The Conference is designed to bring together the life sciences community to share anecdotes, tools and resources to support women involved in all aspects of science, technology, engineering and math. More…
An incredibly important and busy week on so many fronts: the NJ Election, the ongoing Drug Pricing debate in DC and today’s White House release of vaccine requirements for employers. Not for the faint of heart! See BioNJ’s Public Policy Update for the New Jersey Election and Drug pricing news by clicking here.And the link for the White House Vaccination Policies here.
Meanwhile, an incredible lineup of speakers is in place for BioNJ’s Inspiring Women in STEM Conference on December 3. Check out the program here.
Thank you to everyone who joined us last Friday for BioNJ’s 9th Annual C-Suite Summit. From Dr. Peter Marks of the FDA to Dr. Michael Ku of Pfizer, we were excited to have assembled a roster of world-class leaders to consider this past year’s successes and challenges, the next wave of innovation across the value chain and how the industry might deepen and scale its commitment to delivering a positive impact for society. More…
Last week, BioNJ released a new white paper, “Prescription Drug Affordability Boards: Myths vs. Facts on Drug Supply Chain,” that corrects the record on several common myths about Prescription Drug Affordability Boards (PDAB) and their harmful impact on Patients and the medical innovation ecosystem. The BioNJ white paper concludes that policymakers should avoid the creation of a PDAB as a means to control drug costs and should instead adopt solutions that will improve Patient access and deliver savings to the health care system, such as capping Patient out-of-pocket costs and using negotiated rebates to provide savings to Patients. More…
BioNJ recently released the speaker roster for our Ninth Annual C-Suite Summit,entitled “Transitional to the ‘Next Normal’: Biopharma’s Role in Addressing the COVID-19 Crisis and What’s Next,” taking place virtually Friday, October 15, 2021,from 8:30 a.m.-2:15 p.m. After closely monitoring updates from the Centers for Disease Control and Prevention and State and local health agencies, as well as speaking with leading epidemiologists, BioNJ has decided to present this year’s full-day C-Suite Summit virtually, instead of its originally planned in-person format. More…
We are excited to announce BioNJ’s new Value of Medical Innovation Blog. In our first edition, Alliance for Patient Access (AfPA) Executive Director Josie Cooper explains how the Institute for Clinical and Economic Review (ICER) undermines the critical relationship between patients and their providers with its “one-size-fits-all” approach to drug value assessment.
As Labor Day approaches, the BioNJ Team has been busy planning for our upcoming events schedule. Whether in-person or virtual, BioNJ is committed to bringing you quality programming featuring informative plenary sessions as well as interactive networking opportunities.
Earlier this week, BioNJ opened registration for our first live (fingers crossed that we do not need to revert to a virtual experience) event of 2021! Please join us on Friday, October 15, for BioNJ’s Ninth Annual C-Suite Summit, where we’ll reflect on this past year’s successes and challenges, discuss the next wave of innovation across the value chain and share thoughts on how the industry can deepen and scale its commitment to delivering a positive impact for society. Click here for the program agenda and growing list of speakers. We are looking forward to seeing you and your colleagues in-person!
As the country — and the nation — continue to navigate the new “norm” in the era of COVID-19, we, at BioNJ, are extremely proud of the unwavering commitment and tireless work being done by the life sciences industry here in New Jersey. The Garden State has gallantly led the way in research for testing, antivirals, therapeutics and vaccines against this devastating virus.
Core to BioNJ’s mission is helping companies find the talent they need to ensure New Jersey’s life sciences ecosystem has the required expertise to drive medical innovation forward. With this in mind, BioNJ’s Talent Services Career Portal was specifically designed to bring together top talent with leading companies in the New Jersey region.
The COVID-19 pandemic necessitated changes in nearly every aspect of our lives. Nowhere was this more apparent than in our health care system. Among the hardest hit states in the early days of the pandemic, New Jersey’s health care system immediately stepped to the plate to treat and triage COVID-19 Patients. Additionally, the Garden State’s vibrant life sciences ecosystem delivered unprecedented innovation — from providers and others adapting to a new and unknown virus to the ongoing research and development of vaccines and treatments that have played a major factor in our return to “normal.”
As the world continues to navigate the “new” norm, it has never been more important for the life sciences community to come together and support and learn from one another. BioNJ is dedicated to working hard on behalf of our Members — while you are hard at work for Patients. Make sure to take advantage of all the value-driven opportunities available to your organization through your BioNJ Membership.
Thank you to everyone who joined us last week for BioNJ’s 11th Annual BioPartnering Conference. Presented in concert with J.P. Morgan and Johnson & Johnson Innovation on May 18 and 19, the Conference brought together life sciences professionals from 9 countries and 20 states as well as the District of Columbia and featured nearly 70 company and pitch presentations, hundreds of 1:1 partnering meetings and plenary sessions led by industry leaders and world-renowned research institutions from the region.
We hope to see you next week at BioNJ’s Virtual BioPartnering Conference, developed and presented in concert with J.P. Morgan and Johnson & Johnson Innovation. Taking place May 18 and 19, BioNJ’s BioPartnering Conference is a unique opportunity to connect with life sciences executives, investors, institutional collaborators and business development professionals; schedule 1:1 meetings with potential partners; present and watch Company and Start-up Pitch Presentations; hear from industry experts; discuss business and research opportunities with world-renowned institutions and network directly with other conference attendees. Click here for a list of topics and speakers.
COVID-19 has exposed just how vulnerable so many communities are in the face of disease and just how critical access to necessary treatment is to protecting and maintaining patient health. The pandemic has also exposed how deep health inequities continue to leave many underserved communities behind. Unfortunately, lawmakers are increasingly looking to the Institute for Clinical and Economic Review (ICER) and drug value assessment frameworks for how to accurately price new and innovative medical treatments — many of which are being developed by life sciences companies that call New Jersey home. ICER uses the “Quality Adjusted Life Years” (QALY) methodology to determine the value of new drugs and then issues reports on these therapies when they come to the market.
The COVID-19 pandemic has necessitated changes in nearly every aspect of our lives during the last year. Nowhere has this been more apparent than in our health care system. The Coronavirus pandemic has presented an unprecedented challenge to our health care system and had a profound impact on people’s lives and livelihoods.
Thank you to the many companies that have submitted applications to present at this year’s BioNJ’s Virtual BioPartnering Conference, developed and presented in concert with J.P. Morgan and Johnson & Johnson Innovation. Thank you to our partners at JPM and J&JI for their active collaboration, engagement and counsel. It is extraordinary!
Earlier this week we released the agenda and speaker roster for our Inaugural Diversity, Equity & Inclusion…Because It Matters Conference, taking place virtually on March 24 and 25, 2021.
Now that we are one year in and vaccines are a reality, there is so much to think about and plan for! Join us next Thursday, February 25, for BioNJ’s Virtual Briefing where we’ll learn the latest on the vaccine and its variants and hear from those directly in the trenches developing plans for returning to the office and engaging with their Teams through the pandemic. Click here for details.
Thank you to everyone who joined us for yesterday’s BioNJ Board and Member Connection. We were excited to bring our Membership together for this interactive program. During yesterday’s event, BioNJ announced the election of its 2021 Officers and Board Members.
We look forward to seeing our Members on Thursday, February 4 for the first-ever BioNJ Board and Member Connection. This interactive Members-Only program is focused on providing our Members the opportunity to ENGAGE and discuss topics affecting the industry now. We’ll start by welcoming BioNJ’s next Chair of the Board and newest Board Members before hearing presentations by State representatives on New Jersey’s Vaccine Rollout Plan and the newly announced New Jersey Economic Recovery Act.
With the onset of 2021 comes hope and encouragement, as the landmark New Jersey Economic Recovery Act of 2020 was signed into law yesterday by Governor Murphy. The $14.4-billion New Jersey Economic Recovery Act of 2020 features exciting new programs as well as enhancements to existing programs that will result in economic development opportunities for New Jersey while propelling the State’s economic recovery and growth for much of the next decade.
2020 has been challenging to say the least. But, with the unwavering commitment and tireless work being done by the life sciences industry here in New Jersey and beyond, there is a light at the end of the tunnel. We thank the researchers, biopharmaceutical companies, government organizations and Patients who are committed to bringing effective and safe vaccines and therapies to market.
BioNJ continues to lead the way in delivering the New Jersey life sciences message to our policymakers in Washington and Trenton. Last week, President and CEO Debbie Hart issued a statement on the misguided “Most-Favored Nation” rule related to reference pricing for Medicare Part B treatments. BioNJ also included a summary of this legislation in its most recent Public Policy Update while adding our name to a national Patient coalition letter to Congress in opposition to the rule.
It’s been an exciting week with the announcement of promising results from both Pfizer’s and Moderna’s COVID-19 vaccine candidates. As the number of cases and deaths due to the Coronavirus continue to climb at record rates, this news couldn’t come at a better time and amplifies the value, importance and impact of medical innovation. We thank the researchers, biopharmaceutical companies, government organizations and Patients who are committed to bringing effective and safe vaccines to market.
Known as the Medicine Chest of the World, New Jersey is leading the way on COVID-19 research. Join us on Friday, June 5, for a BioNJ COVID-19 Rapid Fire Research Showcase when we bring together 10 companies to share details on their groundbreaking COVID-19 research. From vaccines, cell and gene therapy, treatments and therapeutics, our presenters will highlight the important science coming from the Garden State.
Over the last few weeks, BioNJ has hosted a number of webinars under our new “Business UnUsual Webinar Series: In the Age of COVID-19,” featuring timely topics specifically focused on how they relate to the life sciences community.
We hope this letter finds you safe and well. During these most difficult times, there are numerous examples of brilliance and rays of hope being provided by New Jersey’s robust life sciences ecosystem. As always, we are happy to celebrate them and all of you who make it possible here in the BioLines Weekender!
2019 has come in like a lion. From co-hosting the Wine with BIO Friends Reception and attending the J.P. Morgan Healthcare Conference and Biotech Showcase in San Francisco to testifying before the Assembly Health and Senior Services Committee in opposition to a proposed Prescription Drug Review Commission…….Read the full article
Just prior to the New Year, Governor Murphy unveiled eight picks — including Debbie Hart, President and CEO, BioNJ; Joel Bloom, President, New Jersey Institute of Technology; and Robert Barchi, President, Rutgers University…….Read the full article
2018 has been an exciting year for New Jersey’s life sciences ecosystem. We’ve seen the opening of new incubators supporting our emerging companies, the announcement of promising initiatives to boost New Jersey’s innovation economy by Governor Murphy…….Read the full article
With great enthusiasm we opened registration this week for BioNJ’s 26th Annual Dinner Meeting and Innovation Celebration taking place February 7, 2019 at the Hilton East Brunswick…….Read the full article
We held BioNJ’s Public Policy Committee Meeting, featuring guest speaker Assemblyman Andrew Zwicker, met with numerous New Jersey legislators……Read the full article
We held our Sixth Annual C-Suite Summit to discuss “Healthcare and Biopharma in Transformation: Industry’s New Edge of Opportunity.” Thank you to all who came out to participate in this important industry conversation. In addition to programming, the Team has been busy on the policy front……Read the full article
Hosted a successful Third Annual Beyond Value Frameworks: Defining the Value of Medical Innovation Workshop which brought together multi-stakeholders for an open discussion on how to become more influential regarding framework decisions to ensure Patients have access to the right medications at the right time…..Read the full article
Congratulations to William Lewis, CEO, and the entire Team at Insmed for the ir first ever FDA approval of Arikayce, a new treatment for nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex in adults who don’t respond to conventional treatment…..Read the full article
Since the last BioLines Weekender, we participated in not one but two ribbon cuttings in addition to visiting the brand new headquarters location of OncoSec in Pennington…..Read the full article
The BioNJ Team had a great summer — cruising with our Members, planning future events and working with Governor Murphy and his Administration on initiatives to create new growth opportunities for our industry in the great state of New Jersey……Read the full article
This week we opened registration for our Sixth Annual C-Suite Summit, taking place October 25 at the Bridgewater Marriott. Entitled “Healthcare and Biopharma in Transformation: Industry’s New Edge of Opportunity,”…..Read the full article
Congratulations to BioNJ Board Advisor Dr. Andrew Pecora and the entire Team at BioNJ Member Hackensack Meridian Health on the advancements they are making to New Jersey’s innovative ecosystem. At the ribbon cutting for the Institute for Multiple Myeloma earlier this week…..Read the full article
The BioNJ Team has been enjoying its summer — cruising with our Members, planning future events and working with the administration on initiatives to create new growth opportunities for our industry in the great state of New Jersey…..Read the full article
Congratulations to Congressmen Leonard Lance and Tom MacArthur who were presented with the American Life Sciences Innovation Council’s 2018 Champion of Health Care Innovation Award…..Read the full article
Other than the budget struggles in Trenton, it’s been mostly a fun and very productive two weeks for the BioNJ Team since our last e-newsletter. We discussed the Governor Murphy Administration’s plans for advancing innovation in New Jersey with Tim Sullivan, CEO, New Jersey Economic Development Authority, during BioNJ’s Board Meeting….Read the full article
We led the New Jersey Biotechnology Task Force in its release of recommendations to boost New Jersey’s biotechnology sector, joined the New Jersey delegation at BIO in Boston, attended press conference with Governor Murphy on new STEM initiatives at Stevens Institute….Read the full article
We participated in Students 2 Science and New Jersey Innovation Institute Board Meetings, co-hosted a Congressional Staff Briefing on emergency preparedness…..Read the full article
We hosted our widely successful 8th Annual BioPartnering Conference, in partnership with J.P. Morgan, which brought together nearly 450 industry professionals (vs. 285 last year) from 18 states and 5 countries…..Read the full article
We interviewed BioNJ Entrepreneurship Fellowship candidates and extended an offer to a bright and promising candidate who will serve four 6-month rotations at Pfizer, Rafael Pharmace…..Read the full article
We chaired New Jersey Biotechnology Task Force Committee Meeting, featuring testimony from internationally recognized innovation expert Dr. Susan Windham-Bannister……Read the full article
We’ve had a couple of action-packed weeks for the BioNJ Team, with a number of exciting activities to report on. We…participated in Governor Murphy’s press conference on The Hub in New Brunswick……Read the full article
The BioNJ Team has been busy since our last Weekender, spending time with legislators, members and Patient advocates……Read the full article
It’s been a whirlwind two weeks for the BioNJ Team! We’ve…Met with Congressmen Leonard Lance and Frank Pallone to discuss important industry issues and challenges, attended the grand opening of Celgene’s CAR T facility at Summit West……Read the full article
The industry came out to honor New Jersey’s innovative life sciences companies and leaders, as well as the Patients who inspire them, last Thursday night at BioNJ’s 25th Annual Dinner Meeting and Innovation Celebration……Read the full article
Next Thursday, February 1, BioNJ will celebrate the medical innovation coming from New Jersey’s life sciences industry during its 25th Annual Dinner Meeting & Innovation Celebration. We have a lot to be proud of as New Jersey continues to be one of the top innovation hubs in the world……Read the full article
As reported by BioWorld, “2017 can be called the biggest year yet for the FDA.” With nearly 50% of all new 2017 novel drug and therapy approvals coming from companies with a footprint in New Jersey…..Read the full article